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ABSTRACT 
 
BACKGROUND  
While Blood lipids and lipoproteins are strongly related to coronary 
atherosclerosis, their association with cerebrovascular atherosclerosis is less 
clear. Lipoprotein (a) is considered as an independent risk factor for 
atherosclerosis. Due to distinctive structural homology with plasminogen, it 
interferes with function of plasminogen thus increasing thrombotic risks. Serum 
lipoprotein (a) levels are genetically determined and remain almost continual 
throughout life being minimally affected by gender, nutrition, age, 
environmental factors and drugs. 
Hence the present study was undertaken to estimate the serum lipoprotein 
(a) levels and lipid profile in ischemic cerebrovascular disease and to compare 
the same with matched controls. 
 
AIM OF THE STUDY 
The relation between serum lipids and ischaemic stroke remains 
controversial. Studies of lipid related risk factors in cerebrovascular disease 
have differed significantly in their findings and also in their definition of the 
cerebrovascular end points. Serum lipids are thought to influence the 
pathogenesis of stroke through an atherosclerosis mechanism. Stroke in young 
patients have been shown to be most commonly related to non-atherosclerotic 
reasons.  
The aim of the study was to compare serum lipoprotein (a) level and lipid 
profile in ischaemic cerebrovascular disease patients and matched controls of 
the same age group and to find the association between lipoprotein (a) levels 
and lipid profile in ischaemic cerebrovascular disease.  
 
OBJECTIVE OF THE STUDY 
The study was done to find the association between lipoprotein (a) levels 
and lipid profile in ischaemic cerebrovascular disease.  
 
METHODS 
In this study, a total 80 subjects were included, who were divided into 
two groups, 40 patients with history and clinical features suggestive of ischemic 
stroke and confirmed by CT scan and 40 controls with no clinical history or CT 
scan features suggestive of recent or old ischaemic stroke. All subjects 
underwent a detailed evaluation for hypertension, diabetes mellitus, smoking, 
lipid profile and lipoprotein (a). All ischaemic stroke patients underwent a 
thorough evaluation for the presence of cardiac disease, by means of an ECG 
and 2-D ECHO. 
 
RESULTS 
Ischaemic stroke patients had higher levels of lipoprotein (a). Patients of 
ischemic stroke aged less than 60 years with ischemic stroke had significantly 
elevated lipoprotein (a). Ischaemic stroke patients with normal triglycerides and 
normal total cholesterol were found to have significantly elevated lipoprotein 
(a) when compared to controls. However, the association of plasma lipid 
concentrations in ischemic stroke patients was found to be statistically 
insignificant in this study.  
 
CONCLUSION 
Lipoprotein (a) is an independent marker for ischemic stroke and is 
significantly raised in ischemic stroke patients especially in patients aged less 
than 60 years and in patients with normal cholesterol and triglyceride levels. 
 
KEYWORDS 
Lipoprotein (a); Ischaemic stroke; Cholesterol; Epidemiology 
 INTRODUCTION 
 
Cerebrovascular disease has been shown to be one of the 
frequent causes of long term severe disability(1) and mortality. In 2001, 
WHO estimated that cerebrovascular disease accounted for 5.5 million 
deaths worldwide, equivalent to 9.6 % of all deaths.(2) Two-thirds of 
these deaths occurred in people living in developing countries. Stroke 
had been estimated to cause more than 4 million deaths in 1990, 75% 
of them in developing countries.(3) Hyperlipidemia has been 
established to be a risk factor for ischemic heart disease (IHD) (4). The 
important role of lipids in the prevention of cerebrovascular disease 
has been but a new discovery. 
Serum lipoprotein (a) [Lp (a)] levels are genetically determined 
and considered to be an independent risk factor for atherosclerosis.(5) 
Due to distinctive structural homology with plasminogen, it interferes 
with function of plasminogen thus increasing thrombotic risks. 
Numerous studies have evaluated the association between Lp 
(a) and ischaemic (thrombotic) stroke. A few studies among the many 
provide inconsistent findings regarding Lp (a) as a predictor of 
ischemic stroke. Therefore, this study was undertaken to compare 
 serum lipoprotein (a) and lipid profile in ischaemic cerebrovascular 
disease patients and matched controls. 
 
AIM OF THE STUDY 
The relation between serum lipids and ischaemic stroke remains 
controversial. Studies of lipid related risk factors in cerebrovascular 
disease have differed significantly in their findings and also in their 
definition of the cerebrovascular end points. Serum lipids are thought 
to influence the pathogenesis of stroke through an atherosclerosis 
mechanism. Stroke in young patients have been shown to be most 
commonly related to non-atherosclerotic reasons.  
The aim of the study was to compare serum lipoprotein (a) level 
and lipid profile in ischaemic cerebrovascular disease patients and 
matched controls of the same age group and to find the association 
between lipoprotein (a) levels and lipid profile in ischaemic 
cerebrovascular disease.  
 
OBJECTIVE OF THE STUDY 
The study was done to find the association between lipoprotein 
(a) levels and lipid profile in ischaemic cerebrovascular disease.  
 
 REVIEW OF LITERATURE 
 
 
HISTORY OF LIPOPROTEIN 
 1929: Michel Macheboeuf, reported the isolation from horse serum 
of a stable, water-soluble lipoprotein. 
 1941: Lipoproteins are separated electrophoretically by Blix et al  
 1947: Pederson was able to flotate a b-lipoprotein in the 
ultracentrifuge at the density of 45% saturated magnesium sulfate. 
 1949: Gofman from the University of California at Berkeley 
proposed a new method for the quantitative measurement of serum 
lipoproteins  
 1950: Gofman was then able to associate certain lipoprotein 
fractions with atherosclerosis and xanthomatosis. 
 1963: Ka¨re Berg discovered lipoprotein, Lp(a) in Norway in a 
immunochemical study. 
 1967: Fredrickson made attempts to identify the protein 
components (apopeptides) of the major lipoproteins. 
 1970: Fredrickson cleared that there were four families of peptides 
associated with the major lipoproteins. 
 1976: Jackson discovered that the A-apopeptides were associated 
primarily with the a-lipoproteins (HDL). 
 DEFINITIONS AND CLASSIFICATIONS 
 
Stroke 
 A stroke or cerebrovascular disease, is the rapidly evolving loss 
of brain function(s) due to disturbance in the blood supply to the 
brain.(6) 
 
Ischemic Stroke 
In an ischemic stroke, blood supply to some parts of the brain is 
decreased, leading to dysfunction of the brain tissue in that area. (7) 
Ischemic stroke accounts for over 80% of all cases of stroke. There are 
four main causes for Ischemic stroke are as follows: (1) Embolism (2) 
Thrombosis (3) Systemic hypo perfusion and (4) Venous thrombosis. 
 
Hemorrhagic Stroke 
Intracranial hemorrhage is the accumulation of blood anywhere 
within the skull vault that disrupts the blood supply and chemical 
balance of neurons. This may be intra-axial or extra-axial. Intra-axial 
hemorrhage includes intraparenchymal or intraventricular forms.(8)  
 Transient ischemic attack (TIA) 
TIA is a transient episode of neurologic dysfunction caused by 
ischemia – focal brain, spinal cord or retinal - without acute 
infarction.(9) TIAs share the same underlying etiology as strokes; a 
disruption of cerebral blood flow. But unlike a stroke, the symptoms 
of a TIA can resolve within a few minutes or 24 hours. Brain injury 
may occur in a TIA lasting only few minutes. The occurrence of a TIA 
is a risk factor for eventually having a stroke or a silent stroke.(10) 
 
Reversible Ischemic Neurological deficit (RIND) 
A cerebral infarct that lasts longer than 24 hours but less than 3 
weeks is called a reversible ischemic neurologic deficit or RIND.(11) 
However, RIND symptoms are transitory, happening when blood flow 
to the brain is restricted temporarily. No permanent brain damage 
occurs, but RIND further increase the risk of developing a stroke.(11) 
 
Stroke in evolution 
Stroke-in-evolution is in fact a constellation of situations 
including various causes (lacunar, large infarcts, hemorrhages, and 
distal fields infarcts), various types of evolution and numerous 
pathophysiological mechanisms.(12) It is a progressive neurological 
 deficit over a few hours to days. The number of well-studied clinical 
cases in the literature is astoundingly small.  
 
Completed stroke 
A completed stroke is initiated by irreversible brain injury due 
to the interruption of blood flow.(13) It is rapid in onset with persistent 
neurological deficit with a temporal frame of 96 hours.(14)  
 EPIDEMIOLOGY 
 
Reliable morbidity and mortality estimates for stroke in India 
are inadequate.(15) In India, the Council for Medical Research 
estimated that mortality due to strokes increased by 8% between 1998-
2004.(16)  
The Indian National Commission on Macro – economic and 
Health has estimated that the number of strokes will increase from 
1,081,480 in 2000 to 1,667,372 in 2015.(17) 
 
Prevalence/incidence of stroke in India 
Prevalence data for stroke are inadequate and are confined to 
studies that suffer from frequent bias, small and variable sample sizes, 
and inconsistent diagnostic criteria. The crude prevalence rate for 
India varies widely according to region.(18) (Fig 1,2) 
Stroke increases with age: individual Indian studies have 
assessed that the occurrence rates increases from 21/100,000 for the 
20-40 age group to 625/100,000 in the 60+ year age group. Similarly, 
the incidence rates increase from 27-34/100,000 in the 35-44 age 
groups to 822-1116/100,000 in the 75+ age group.(19) However in 
 India, the prevalence of stroke in younger individuals is high (18-32% 
of all stoke cases) compared with high-income countries.  
 
Table 1:  Death from cerebrovascular disease in India, China and 
established market economies (EME) in millions 
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Stroke prevalence studies in India 
The crude prevalence rate appears to be higher in urban 
compared to rural populations. The Parsi population in Mumbai 
appears particularly at risk, compared with the other Indian 
population.(20) 
The overall age adjusted prevalence rate for stroke is estimated 
to lie between 84-262/100,000 in rural and between 334-424/100,000 
in urban areas. 
 
 
 
  
Table 2:  Stroke prevalence studies in India 
First Author Year Location 
Sample 
size 
Crude 
prevalence 
per 100,000 
Age-adjusted 
prevalence per 
100,000 
Urban 
Dalal PM 1997 Mumbai 145456 220 – 
Banerjee TK 2001 Kolkata 50291 147 334 
Gourie-Devi M 2004 Bangalore 51502 136 – 
Rural 
Das SK 1996 
West 
Bengal 
37286 126 – 
Saha SP 2003 
West 
Bengal 
20842 147 – 
Gourie-Devi M 2004 Karnataka 51055 165 262 
 
 Figure 1: Crude prevalence rates for stroke in rural India 1970-
2004 
 
Figure 2: Crude prevalence rates for stroke in urban India 1973-
2004 
 
 
 Annual incidence rates for stroke in India 
While discrete studies have reported varying annual incidence 
rates for stroke, the Global Burden of Disease Study estimated a 
population-based annual stroke incidence of India to be 89/100,000 in 
2005, which is projected to increase to 91/100,000 in 2015 and to 
98/100,000 by 2030.(17) 
 
Table 3:  Annual incidence rates for stroke in India 
First author Year Location 
Sample 
size 
Annual 
incidence 
per 
100,000 
Age-
adjusted 
annual 
incidence 
per 100,000 
Urban 
Banerjee TK 2001 Kolkata 50291 36 105 
Dalal PM 2005 Mumbai 56861 145 152 
Sridharan 2009 
Trivandru
m 
741000 116 135 
Rural 
Abraham J 1970 
Tamil 
Nadu 
258576 13 - 
Sridharan 2009 
Trivandru
m 
185000 119 138 
Battacharya 
S 
2005 
West 
Bengal 
20842 124 262 
 
 RISK FACTORS FOR ISCHAEMIC STROKE 
 
Non-Modifiable Risk Factors  
Age, ethnicity, gender, race and heredity have been recognized 
as markers of risk for stroke. Despite these factors being non-
modifiable, their presence requires vigorous treatment of risk factors 
that can be modified. 
AGE 
Age is the most important risk factor for stroke. For each 
successive 10 years after the age of 55, the incidence of stroke more 
than doubles in both sexes.(21)  
SEX 
Stroke occurrence rates are 1.25 times higher in men. Women 
being likely to live longer than men, the annual mortality rate among 
women is higher.(22) 
HEREDITARY/ FAMILIAL FACTORS 
Probable reasons for genetic tendency for stroke are genetic 
determinants of other stroke risk factors, and an exposure to 
environmental or lifestyle risks. Studies suggest that men with a 
 maternal history of stroke and women with a family history of stroke 
(23) are at increased risk. 
RACE/ ETHNICITY 
Stroke incidence and mortality rates differ widely between 
racial groups. Afro-Americans are at twofold risk of mortality due to 
stroke as compared to whites.(24) Asians, particularly Chinese and 
Japanese, have elevated stroke incidence rates.(25) 
Potentially Modifiable Risk Factors for Ischemia Stroke 
HYPERTENSION 
Hypertension is high risk factor for all types of stroke. The 
relationship of diastolic blood pressure and stroke is log linear 
throughout normal range of pressure. The systolic blood pressure and 
stroke had a stronger and consistent relationship than diastolic blood 
pressure. Hypertensive patients had four times more chances of having 
stroke, when systolic blood pressure was ≥160 mm Hg and/or the 
diastolic blood pressure  was ≥95 mm Hg.(26)    
CARDIAC DISEASE 
Various cardiac diseases have been proved to increase risk of 
stroke. Atrial fibrillation (AF) is one of the most important risk factor. 
Increasing age predisposes to developing AF. After 55years of age, 
incidence of AF doubles for every ten years. (27) Cardiac valve 
 abnormalities, especially mitral stenosis, mitral annular calcification 
and mitral valve prolapse. Calcification of the mitral valve annulus 
was associated with a doubled rate stroke rate in follow-up.(28)  
Recent studies have shown that valvular strands attached to the 
mitral and aortic valves as risk factor for stroke. These are usually 
identified by transesophageal echocardiography (TEE). Left atrial 
enlargement has also been shown to be a well-known risk factor for 
stroke. A 1cm increment in size of left atrium increased the age-
adjusted risk of stroke by approximately two times.(29) Other causes 
may include anterior wall myocardial infarction and left ventricular 
aneurysm. 
DIABETES AND GLUCOSE METABOLISM 
Individuals with diabetes have been shown to be prone to 
atherosclerosis and have an increased prevalence of atherogenic risk 
factors specially obesity, hypertension, and dyslipidemia. Diabetes 
also has been shown to be an independent risk factor for ischemic 
stroke with a relative risk of 1.8-3.0.(30) 
In the Framingham study, impaired glucose tolerance doubled 
the risk of ischaemic stroke.(31)  
 
 
 TRANSIENT ISCHEMIC ATTACKS (TIA) 
The risk of stroke in patients with TIAs is about 4%. After 
adjusting for major cardiovascular risk factors that predispose a 
patient to stroke, a TIA remains an important independent risk factor 
for both stroke and myocardial infarction.(32) TIAs are associated with 
atherosclerotic lesions at the origin of the internal carotid artery (ICA) 
or intra cranial portion of ICA, stem of middle cerebral artery, 
junction of vertebral and basilar arteries, and occlusion of small 
vessels. Hemispheric ischemic symptoms have usually been associated 
with high grade stenotic lesions of the internal carotid artery.(33)  
LIPIDS 
Whereas hypercholesterolemia is an important variable risk 
factor for coronary heart disease, the relation of lipid variables with 
ischeamic cerebrovascular disease remains undefined.(34) However, a 
number of studies clearly support the relation between total and LDL 
cholesterol and the protective action of HDL cholesterol on 
extracranial carotid atherosclerosis.(35-37) 
CIGARETTE SMOKING 
Cigarette smoking increases the relative risk of ischemic stroke 
almost two times,(38) with apparent dose-response relation, both pack 
years and cigarettes per day being influential factors. In both the 
 Nurses' Health Study(39) and the Framingham Study(40) termination of 
smoking reduces stroke risk.  
ALCOHOL 
Moderated alcohol intake upto sixty gram per day may reduce 
cardiovascular disease and stroke. A J-shaped association was found 
between moderate alcohol consumption and ischemic stroke.(41)  
Increased consumption of alcohol has been shown to increase the risk 
for ischemic stroke.(42) Hypertension, arrhythmias, hyperviscosity, 
hematocrit changes, clotting factor changes and increased platelet 
aggregation as a consequence of binge drinking may contribute to the 
development of stroke. 
ILLICIT DRUG USE 
Drug abuse accounts for around 10% of young adult stroke. 
Abuse with cocaine is related to stroke.(43) Other drugs implicated in 
stroke are heroin, amphetamines, D-Lysergic Acid, and marijuana.  
LIFESTYLE FACTORS 
Diverse lifestyle factors like obesity, physical activity, diet, and 
acute triggers such as emotional stress have been linked with increased 
stroke risk. Obesity has been associated with higher levels of blood 
pressure, blood glucose, and serum lipids, which are independent risk 
factors for stroke. There is a protective effect of moderate physical 
 activity on stroke in both men and women.(44) Increased intake of fish 
rich in unsaturated fatty acids, green tea, and milk were protective for 
stroke, while food intake  rich in fat and cholesterol have been shown 
to be harmful.(45) 
ORAL CONTRACEPTIVES 
In recent times, a study of low-dose oral contraceptives (<50 µg 
estrogen) revealed no increased risk of stroke in more than 3.6 million 
woman-years of observation.(46) 
MIGRAINE 
Though migraine has been recognized as an independent risk 
factor for ischemic stroke in men older than 40 in the Physicians' 
Health Study, (47) no association has been demonstrated by other 
studies. 
HEMOSTATIC AND INFLAMMATORY FACTORS 
Hemostatic factors have not been associated with increase in 
incidence of cardiovascular disease. However two studies linked 
fibrinogen to increased stroke risk. Fibrinogen increases viscosity, 
atherogenesis, platelet aggregation and enhances clot creation that act 
as the substrate for thrombin.(48) 
The tissue-type plasminogen activator (TPA) system, has also 
been shown to be independently related with risk of stroke.(49) 
 HOMOCYSTEINE 
Blood levels of homocysteine  are determined genetically and 
altered by intake of vitamins B6, vitamin B12, and folic acid. High 
homocysteine level is a strong, independent risk factor for stroke in 
middle-aged men.(50) 
GENETIC FACTORS 
Recently a single gene disorder responsible for ischemic stroke 
has been described. The gene for cerebral autosomal dominant 
arteriopathy with sub cortical infarct and leukoencephalopathy 
(CADASIL) has been localized to chromosome 19 which also hosts 
the gene for Familial Hemiplegic Migraine. Other genetic disorders 
associated with stroke include Ehler Danlos Syndrome, Marfan’s 
Syndrome, Sickle cell disease and Protein C and Protein S Deficiency, 
Familial Cerebral Amyloid angiopathy, mitochondrial cytopathy, and 
dysfibrinogenemia. 
 
 Table 4:  Risk Factors for Stroke
(51)
 
Well-documented risk factors Less well-documented risk factors 
Modifiable, value established Potentially modifiable  
Hypertension Cardiac disease 
Cardiac disease Cardiomyopathy 
Atrial fibrillation Segmental wall motion abnormalities 
Infective endocarditis Nonbacterial endocarditis 
Mitral stenosis Mitral annular calcification 
Recent large myocardial infarction Mitral valve prolapse 
Cigarette smoking Valve strands 
Sickle cell disease 
Spontaneous echocardiographic 
contrast 
Transient ischemic attacks Aortic stenosis 
Asymptomatic carotid stenosis Patent foramen ovale 
Potentially modifiable Atrial septal aneurysm 
Diabetes mellitus Elevated blood cholesterol and lipids 
Hyperhomocysteinemia Use of oral contraceptives 
Left ventricular hypertrophy Consumption of alcohol 
Non-modifiable Use of illicit drugs 
Age Physical inactivity 
Gender Obesity 
Hereditary/familial factors Elevated hematocrit 
Race/ethnicity Dietary factors 
Geographic location 
Hyperinsulinemia and insulin 
resistance 
 Acute triggers (stress) 
 Migraine 
 Hypercoagulability and inflammation 
 Fibrin formation and fibrinolysis 
 Fibrinogen 
 Anticardiolipin antibodies 
 Genetic and acquired causes 
 Subclinical diseases 
 Intimal-medial thickness 
 Aortic atheroma 
 Socioeconomic features 
 Non-modifiable 
 Season and climate 
 Table 5:  Causes for Ischemic Stroke
(52) 
Common Causes Uncommon Causes 
Thrombosis  
Lacunar stroke (small 
vessel)  
Large vessel 
thrombosis  
Dehydration 
Embolic occlusion  
Artery-to-artery  
Carotid bifurcation  
Aortic arch  
Arterial dissection 
Cardioembolic 
Atrial fibrillation  
Mural thrombus  
Myocardial infarction  
Dilated 
cardiomyopathy  
Valvular lesions  
Mitral stenosis  
Mechanical valve  
Bacterial endocarditis 
Paradoxical embolus  
Atrial septal defect  
Patent foramen ovale 
Hypercoagulable disorders  
Protein C deficiency  
Protein S deficiency  
Antithrombin III deficiency  
Antiphospholipid syndrome  
Factor V Leiden mutation 
Prothrombin G20210 mutation 
Systemic malignancy  
Sickle cell anemia 
β-Thalassemia  
Polycythemia vera 
Systemic lupus erythematosus 
Homocysteinemia 
Thrombotic thrombocytopenic purpura 
Disseminated intravascular coagulation  
Dysproteinemias 
Nephrotic syndrome  
Inflammatory bowel disease  
Oral contraceptives 
Venous sinus thrombosis 
Fibromuscular dysplasia  
Vasculitis 
Systemic vasculitis  
Primary CNS vasculitis 
 Common Causes Uncommon Causes 
Atrial septal aneurysm  
Spontaneous echo 
contrast 
Meningitis (syphilis, tuberculosis, fungal, 
bacterial, zoster) 
Cardiogenic  
Mitral valve calcification  
Atrial myxoma 
Intracardiac tumor 
Marantic endocarditis  
Libman-Sacks endocarditis 
Subarachnoid hemorrhage vasospasm  
Drugs : Cocaine, amphetamine  
Moyamoya disease  
Eclampsia 
 
 Plate : 1 - Cerebral Angiogram 
 
 
Early Stroke Findings on CT – 1 
 
 
Hyper-
density in 
the Proximal 
Right MCA 
 
 IMAGING IN STROKE 
Radiological Tests: 
 Cerebral Angiogram 
 Computed Tomography (CT) 
 With or without contrast 
 CT angiogram (CTA) 
 Magnetic Resonance Imaging (MRI):  
 With or without contrast 
 T1 or T2 weighted (T1WI, T2WI) 
 Fluid attenuated inversion recovery(FLAIR) 
 Diffusion weighted image (DWI) 
 MR angiogram 
 
CEREBRAL ANGIOGRAM 
 Gold standard in the past 
 Outdated and replaced by MRI/MRA 
 High risk of producing further thrombus formation in brain and 
causing renal failure  
 
CT WITHOUT CONTRAST 
 Distinguish between ischemic and hemorrhagic stroke. 
 Normal CT in patient with <3 hrs of symptoms → can begin 
tissue plasminogen activator therapy if there is no other 
contraindications. 
 Plate 2 : Early Stroke Findings on CT -1 
 
Normal  
Hyperdense  
Insular Cortex 
Internal 
Capsule 
Damaged 
Region 
 CT FINDINGS IN CEREBRAL INFARCTION 
(53, 54)
 
<12 HRS – THE HYPERACUTE PHASE 
 Normal 50-60% 
 Hyperdense artery (dense MCA sign) 
 Obscuration of the lenticular nucleus 
 Loss of gray-white interfaces (insular ribbon sign) 
12-24 HRS – THE ACUTE PHASE: 
 Sulcal effacement 
 Low density basal ganglia 
24 HOURS – 6 WEEKS – THE SUBACUTE PHASE: 
 Increasing mass effect 
 Wedge-shaped low density area involving gray and white 
matter 
 Possible hemorrhagic transformation 
> 6WEEKS – THE CHRONIC PHASE: 
 Parenchymal hypodensity with well-defined margins 
 Necrotic areas in larger ischaemic foci  evolve towards 
porencephalic cavitation, with accompanying dilation of the 
ipsilateral ventricle and adjacent subarachnoid cisterns 
 Some cases may show an ipsilateral displacement of midline 
structures 
 MRI Findings in Cerebral Infarction
(54)
 
Immediate : Hyperintense on DWI, IV contrast enhancement, 
Perfusion alterations 
<12 hrs : Sulcal effacement, gyral edema, loss of gray-white 
interfaces on T1 
12 to 24 hrs : Hyperintensity on T2, Meningeal enhancement adjacent 
to infarct, Mass effect 
1 to 3 days : IV and meningeal enhancement begin decline, Signal 
abnormalities striking on T1WI, T2WI, Possible hemorrhagic 
transformation 
MRI-T2 Weighted Image : T2W: good anatomical detail, T2 signal 
hyperintensity in R, MCA territory: R insula, basal ganglia and 
internal capsule 
MR-DWI : Findings similar to those in T2WI → hyper-intensityin R, 
T2 signal hyper-intensity in R, MCA territory: R insula, basal ganglia 
and internal capsule. Fluid attenuated inversion recovery images are 
particularly useful in hyperacute cortical infarct within 3 hours of 
onset. (55) 
 SERUM BIOCHEMISTRY 
Serum Lipids 
Lipids are water insoluble but are soluble in alcohol and other 
organic solvents.(56) When dietary fats are digested and absorbed into 
the small intestine, they progressively re-form into triglycerides, 
which are then packaged into lipoproteins. 
CLASSIFICATION OF LIPIDS 
Figure 6: Classification of Lipids  
 
1. Simple Lipids 
Neutral fats – Triglycerides, Waxes 
2. Conjugated Lipids (polar lipids) 
Phospholipids, Cerebrosides, Sulfolipids  
 
 3. Derived Lipids 
Fatty acids, Fatty alcohols, Fatty aldehydes, Hydrocarbons and 
Vitamins A, D, E, K 
4. Miscellaneous 
Soaps, Colouring matters, Oxidative polymers, Thermal 
polymers. 
Cholesterol 
Cholesterol is a waxy steroid of fat that is produced in the liver 
or intestines and reduces the fluidity of cell membrabes.(57) It is also an 
important component for the production of bile acids, steroid 
hormones, and Vitamin D. Cholesterol circulates in the bloodstream as 
lipoproteins. 
Low-density lipoprotein (LDL) cholesterol is the "bad" 
cholesterol because elevated LDL levels are related with an increased 
risk of coronary artery disease.  
 LDL levels less than 100 mg/dL are considered optimal. 
 LDL levels between 100 – 129 mg/dL are considered near or 
above optimal. 
 LDL levels between 130 – 159 mg/dL are considered borderline 
high. 
 LDL levels between 160 – 189 mg/dL are considered high. 
 LDL levels at or above 190 mg/dL is considered very high. 
 A HDL level more than 60 mg/dL is considered high. A high 
HDL level is considered very healthy, since it has a protective role 
against heart disease. An undesirable level of HDL is any level below 
40 mg/dL. In this case, low HDL levels may contribute to heart 
disease. 
Lipoprotein 
A lipoprotein consists of a nonpolar lipid core and a single 
surface layer of amphipathic lipids. Lipids usually do not travel alone 
in the blood. Instead, they bind to a protein that will transfer it to its 
correct destination in the body.(58) 
CLASSIFICATION OF LIPOPROTEINS 
Figure 7: Classification of Lipoprotein 
 
 
 The different types of lipoproteins circulating in the body are, 
 Chylomicrons 
 Very low density lipoproteins (VLDL) 
 Intermediate density lipoproteins (IDL) 
 Low density lipoproteins (LDL) 
 High density lipoproteins (HDL) 
These particles transport insoluble lipids in the blood can be 
harmful (VLDL, IDL, LDL) or useful (HDL) to our health. 
During the first pass through the gastrointestinal system, 
lipoproteins are wrapped as chylomicrons, secreted into the 
circulation, are transformed into chylomicron remnants, and then 
finally transported to the liver (59). There they are re-packaged as a 
series of smaller, denser lipoprotein "particles" and are re-secreted 
back into the circulation. However a working knowledge of the 
elements of lipid metabolism is required in order to ensure proper 
recognition and supervision of dyslipoproteinemia.(60) Small, dense 
LDL particles, with the minor particles being more atherogenic. 
In the new US National Cholesterol Education Program (NCEP) 
guidelines, the "non-HDL" sub fraction of cholesterol has become the 
new objective of measurement and treatment.(61) To compute this 
 parameter, the clinician measures total cholesterol (TC) and then 
determine the non-HDL level according to the formula: 
Non-HDL = TC - HDL 
STRUCTURE OF LIPOPROTEIN 
The lipoprotein molecules that we ingest are repackaged into 
particles so that they can be combined into a food delivery and fat 
elimination system.(62) 
Figure 8: Structure of Lipoprotein 
 
 
As shown in the figure, all of these particles are assembled as 
lipid "globules," or particles, with a monolayer phospholipid 
membrane.  
 The enlargement of the cell membrane on the figure shows the 
components of the monolayer phospholipid membrane.The lower left 
of the figure affords a look "inside" the lipoprotein particle, where we 
see the "fatty core," consisting of cholesterol, cholesterol esters, 
triglycerides (the dark brown "jelly fish"), and free fatty acids (the 
"legs" of the jelly fish). 
All lipoprotein particles are built in this manner; the particles 
vary in their size and density or, in the case of the HDL vs non-HDL, 
in the apolipoprotein molecule implanted in the surface membrane 
(Apo A vs Apo B). 
Apolipoproteins 
Cholesterol and triglycerides are transported everywhere in the 
body by the lipoproteins: HDL, LDL, IDL, VLDL, and chylomicrons. 
(63)  These lipid-protein complexes all have alike structures but are 
different sizes, densities and compositions. The outside shell is a 
monolayer of polar lipids: phospholipids and free cholesterol.  The 
core comprises neutral lipids: triglycerides and cholesterol esters.   
 
 Figure 9: Structure of Apolipoprotein 
 
Apolipoproteins relate with transportation proteins and 
lipoprotein receptors as well as being co-factors for lipolytic enzymes. 
Lipoproteins are used in blend with other factors such as weight, blood 
pressure and family history to assess cardiovascular risk and to select 
and monitor treatment. (64)   
CLASSIFICATION OF APOLIPOPROTEINS  
Apolipoprotein A-1 and A-11 
Apo A-I and Apo A-II are the core protein components of HDL 
cholesterol. (65)  HDL participates in removing excess cholesterol from 
the tissues for removal by the liver.  Apo A-I is non-atherogenic but 
increased levels of Apo-II appear to promote atherosclerosis by 
moving Apo A-I in HDL and inhibiting reverse cholesterol transport. 
 Apolipoprotein B 
Apo B is a component of LDL cholesterol and allows tissue 
cells to take up cholesterol. Elevated levels of Apo B indicate 
increased cardiovascular threat even when total and LDL cholesterol 
levels are within the typical range.(66) 
Apolipoprotein C-I1 and C-11 
Apo C-II and Apo C-III have antagonistic excitatory and 
inhibitory properties on lipoprotein lipase, which breaks down 
lipoproteins and hydrolyses triglycerides in VLDL and chylomicrons 
for absorption into tissue cells.  Apo C-II deficiency leads to 
hypertriglyceridemia; genetic Apo C-III deficit increases the rate of 
triglyceride clearance.  Low Apo C-II and raised Apo C-III levels are 
associated with a variety of diseases such as type 2 diabetes, 
hypertriglyceridemia and hyperbilirubinemia. 
Apolipoprotein E 
There are three comparable isoforms of Apo E: Apo E2, E3 and 
E4 with E3 being the most common.  Apo E has a variety of purposes 
depending on which lipoprotein it is in.  Apo E deficiency gives rise to 
high cholesterol and triglyceride levels, promoting atherosclerosis.  
The polymorphism has been related with diseases other than 
 cardiovascular disease, for example E4 is implicated in Alzheimer’s 
disease.(67) 
Lipoprotein Metabolism 
Lipoprotein metabolism has a crucial role in atherogenesis. It 
includes the transport of lipids, particularly cholesterol and 
triglycerides, in the blood.(68) The intestine absorbs dietary fat and 
packages it into chylomicrons, which are transported to peripheral 
tissues. The enzyme lipoprotein lipase breaks down chylomicrons in 
muscle and adipose tissues, and fatty acids are taken up by these 
tissues.(69) The enzyme lipoprotein lipase is localized to the walls of 
blood capillaries. Chylomicron remnants are taken in the liver by 
receptor mediated endocytosis apo E. Very-low-density lipoproteins 
(VLDLs) are synthesised in the liver and intestine. They contain 
endogenous triglycerides and are hydrolysed by lipoprotein lipase to 
intermediate-density lipoproteins (IDLs). IDLs are then taken up by 
the liver through binding to the LDL receptor (LDLR), as well as 
other routes or are converted to LDL. LDL makes cholesterol 
available to extra hepatic tissues. Liver and other extra hepatic tissues 
express LDL (Apo B-100, E) receptor. Approximately 70% of LDL is 
degraded in the liver with the remainder portion in the extra hepatic 
tissues. 
 Plate 3 : CETP and its role in HDL metabolism 
 
 High-density lipoproteins (HDLs) are formed in the intestine and the 
liver through the secretion of lipid-free ApoA-I. HDL acts as a 
repository for the apoC and apoE required in the metabolism of 
chylomicrons and VLDL. 
Figure 10: Lipoprotein metabolism 
 
HDLs facilitate the efflux of cholesterol from tissues through 
the actions of ABCA1(reverse cholesterol transport). Nascent HDL 
consists of discoid phospholipid bilayer containing apoA and free 
cholesterol. The cholesterol in nascent HDLs is esterified to 
cholesteryl ester by lecithin cholesterol acyl transferase (LCAT).  
The cholesterol in HDLs circulates back to the liver through 
uptake by the receptor SR-BI, and by transfer to LDLs and VLDLs 
through the cholesteryl ester transfer protein (CETP). The lipid 
content of HDLs is altered by the enzymes hepatic lipase, endothelial 
lipase and by the transfer proteins, affecting HDL catabolism.(70) 
 LIPOPROTEIN (A) – LP (A) 
Figure 12: Structure of Lipoprotein (a) 
 
Lipoprotein(a) is a lipoprotein subclass. It is an accepted risk 
factor for atherosclerotic diseases such as coronary heart disease and 
stroke. (71) 
Lp(a) has prebeta pattern in Electrophoresis, size being 4.9A°, 
and mass 3.8-4.60 x 10-6. The half-life of Lp(a) in the circulation is 
about three to four days. 
Lipoprotein(a) consists of an LDL-like particle and the 
particular apolipoprotein(a), which is covalently bound to the apoB-
100 of the LDL like element. Lp(a) plasma concentrations are 
extremely heritable and mainly controlled by the apolipoprotein(a) 
gene situated on chromosome 6q26-27. Apo(a) proteins differ in size 
due to articulation at the protein level.(72) 
 There is an inverse correlation between the size of the apo(a) 
gene kringle IV repeats resulting in size polymorphism and the Lp(a) 
plasma concentration. This is caused by a variable rate of degradation 
of the apo(a) protein prior to its secretion for Lp(a) assembly.(73) 
Apo(a) is articulated by liver cells, and the assembly of apo(a) and 
LDL particles appears to take place at the outer hepatocyte surface. 
Lp(a) levels may be influenced in many conditions like Nephrotic 
syndrome, malignancies, chronic renal failure, and hypothyroidism. (74-
80) 
 
Lipid variables and the risk of stroke 
TOTAL CHOLESTEROL (TC) AND STROKE  
Initial studies found no consistent results of elevated serum TC 
values as a predictor of stroke related mortality, with few studies 
inversely correlating TC values with death due to stroke. A meta-
analysis of 13000 strokes in a total of 450000 people, found no 
significant association between serum TC levels and stroke. (81) The 
Framingham heart study found a variable yet positive correlation 
between TC levels and the risk of cerebrovascular disease among 
women of different age groups. Studies have showed an inverse 
association between TC values and the risk of intracerebral 
 haemorrhage, independent of age and sex. However, a significant 
linear relation was also found between TC values and ischaemic 
stroke.(81) 
Large studies like the Honolulu heart study in migrants from 
Japan and the Multiple Risk Factor Intervention Trial screening study 
have shown an upsurge in non haemorrhagic stroke that was seen at 
the zenith of TC concentrations. 
TG CONCENTRATIONS AND STROKE  
The postprandial hypertriglyceridaemia is related with carotid 
artery atherosclerosis.(81) Despite a disagreement between the 
relationship of serum triglyceride values and the risk of 
cerebrovascular disease, a log linear association between serum 
triglyceride concentrations and ishaemic stroke was found. Further, 
this association was not related to age and sex.(81) 
HDL CHOLESTEROL AND STROKE  
Many studies have reported an inverse relation between HDL 
levels and the risk of stroke. (81, 82) 
APOLIPOPROTEIN E (APO E) PHENOTYPES AND STROKE 
Apo E phenotypes have been variably associated with stroke. 
While apo E2 and apo E4 have been found to increase the risk, apo 
 E3/E3 phenotype has been associated with a protective effect against 
ischemic stroke. (83) 
LP (A) AND STROKE 
Apart from the well-established risk factors for strokes (such as 
increasing age, hypertension, diabetes, smoking, or the presence of 
vascular disease), the possibility that Lp(a) is a risk factor for 
ischaemic stroke has been shown in several studies.(81)  
Studies favouring Lp(a) as a risk factor for stroke 
In a case control study, serum Lp(a) values were expressively 
greater in patients with ischaemic stroke in comparison to healthy 
individuals. This difference was also obvious in a subgroup of subjects 
between 30 to 69 years.(81) 
A Meta-analysis by Smoulder et al demonstrated that Lp (a) is a 
risk factor for incident stroke.(82) Bostom et al found Lp (a) to be an 
independent indicator for stroke.(83) Nagayama et al showed that 
liprotein (a) level is very significant in atherothrombotic stroke 
(p<0.01)(84). 
Vavernova et al studied Lp(a) values in 45 patients with stroke 
(younger than 55 years of age) and their first degree relations. (85) They 
reported increased serum Lp (a) levels in patients with stroke. They 
also reported that Lp (a) levels were genetically determined. 
 Van Kooten and colleagues found an increased Lp(a) to be 
associated with increased risk of stroke while not influencing the 
stroke characteristic or the prognosis in such patients.(86) 
Peng et al examined the relation between serum lipids, apoE 
genotypes, and the risk of ischaemic stroke in a case controlled study 
of 90 patients. They found that serum Lp(a) concentrations and the 
apoE4 genotype were prominent predictors for ischaemic stroke in 
addition to the previously established risk factors such as 
hypertension, personal history of  stroke, and smoking.(87)  
Kario and colleagues reported that a hypercoagulable state, 
endothelial damage, and increased Lp(a) concentrations predisposed 
asymptomatic, high risk, elderly Japanese patients (aged 44 to 93 
years) to silent multiple lacunar strokes. Raised Lp(a) values specially 
those > 30 mg/litre was found to be associated with more number of 
lacunes.(88)   
Studies not supporting Lp (a) as a risk factor for stroke 
The association between Lp(a) and stroke has been disputed by 
some investigators. Hachinski et al,(89) in a case control study, 
demonstrated that increased LDL and TG levels correlated with 
atherothrombotic stroke risk, while there was no significant variance 
 in the Lp(a) concentrations or the distribution of apoE phenotypes 
among patients and controls. 
In a study conducted in Department of Bio-chemistry Sri 
Devaraj Medical College, Kolar showed no statistical significant 
difference in Lp(a) between controls and thrombotic stroke (90). 
The possibility of anticipating ischaemic stroke by the 
estimation of plasma Lp(a) concentrations and antibodies to 
Chlamydia pneumoniae was investigated by Glader et al.(91) They 
found no relationship between baseline plasma Lp(a) values, the 
presence of anti - C. pneumoniae antibodies, and future ischaemic 
cerebral infarctions. They found no interaction between high Lp(a) 
values and anti-C. pneumoniae antibody titres.  
A prospective study in Finland found no relationship between 
Lp(a) or plasma homocysteine and atherosclerosis.(92)  
Interventions for the reduction of Lp (a) 
DIETARY MODIFICATION   
Saturated fatty acids, n-3 polyunsaturated fatty acids, palm oil 
may slightly reduce Lp(a) values. (93) 
NICOTINIC ACID  
Nicotinic acid has a good but inconsistent, effect on Lp(a) 
concentrations. Large doses of this drug are difficult to tolerate. (94)  
 STATINS 
The Scandinavian simvastatin survival study (4S) showed that 
simvastatin at 20-40 mg daily reduced the combined occurrence of 
TIA and stroke by 29% (36). The cholesterol and recurrent events 
(CARE) trial evaluated the role of pravastatin (40 mg daily) in 
reducing the relative risk of stroke. It was shown that it reduced the 
risk by as much as 32%, over a median follow up period of five years. 
In the long term interference with pravastatin in ischaemic disease 
(LIPID) study, pravastatin (40 mg daily) reduced the relative risk of 
stroke by 19%. These beneficial effects on stroke and myocardial 
infarction occur despite a statins causing a slight increase in 
circulating Lp(a) values.  
FIBRATES 
Fibrates decrease fibrinogen and possibly Lp(a) and oxidised 
LDL values (95). In bezafibrate infarction prevention study, gemfibrozil 
(1200 mg daily) reduced total stroke in comparison to the placebo 
group. TIA in the same trial was reduced from 4.2% to 1.7%, and 
carotid endarterectomy was significantly reduced. However, LDL 
values were fundamentally unchanged. 
 
 
 DIABETES 
Tight glycaemic control may beneficially influence Lp(a) 
values. In type 2 diabetes, glycosylation of Lp(a) has been shown to 
interfere with its catabolism. (96) 
HORMONAL TREATMENT 
Hormonal replacement therapy (HRT) associated with a 
reduction in the risk of evolving coronary artery disease, affects 
cholesterol, Lp(a), and homocysteine concentrations, especially in 
postmenopausal women. (97) 
Thyroid hormone replacement treatment decreases Lp(a) 
concentrations, possibly due to its effect upon apo(a) production, or 
probably Lp(a) assembly. 
FUTURE TARGETED INTERVENTION  
Lp(a) undergoes further modifications like oxidation and 
proteolysis after entry into the wall of the artery.  These post-
translational events could be potential targets for therapeutic 
intervention in future. (98)  
 
 
 METHODOLOGY 
 
The study was conducted in the Government Mohan 
Kumaramangalam Medical College, Salem, Tamil Nadu, India. 
Approval of the Institutional Ethical Committee was obtained prior to 
the study. In this study the sample size was 80 subjects admitted in the 
ward during the period of October 2009 to November 2011, who were 
divided into two groups, 40 cases diagnosed as ischaemic stroke 
(confirmed by CT brain) and 40 control which was matched for age 
and gender. The study consists of history taking, clinical examination 
and biochemical assay. Study subjects were selected after having 
obtained consent. 
All 40 cases were examined and lab investigations were done 
including CT scan, lipid profile and lipoprotein (a)estimation. All 
ischaemic stroke patients underwent cardiac evaluation. 
Inclusion Criteria for Cases 
Patients admitted in the ward with cerebrovascular event and 
CT scan showing acute large vessel infarct. 
Exclusion Criteria for Cases 
 Patients with hemorrhagic stroke. 
 Patient with cardiovascular cause for emboli. 
  Patient on medications altering lipid metabolism (sex steroids, 
statins) 
 Patients having lacunar infarct. 
Inclusion Criteria for Controls 
The patients admitted in the ward without any history, clinical 
findings or CT evidence of any previous cerebral infarct (if available) 
or cardiac illness like scorpion sting, unknown bite with no signs of 
envenomation, oleander seed poisoning with no signs of toxicity, acid 
peptic disease. 
Study Parameters 
HYPERTENSION 
Patients were diagnosed with hypertension if systolic blood 
pressure ≥ 140 mm of Hg or diastolic blood pressure ≥ 90 mm of Hg 
or both as per the guidelines of JNC VII report or if the patient was a 
known hypertensive. 
DIABETES MELLITUS 
Patients with fasting blood sugar ≥ 126 mg%, 2 hours post 
prandial blood sugar ≥ 200 mg% and known diabetics on treatment. 
SMOKING 
A person with history of smoking any tobacco product, 
regularly or occasionally. 
 Test Procedures 
BLOOD COLLECTION 
Blood was collected from all patients using perfectly dry and 
sterile syringes by Venipuncture done in the cubital fossa. 
LIPID PROFILE ESTIMATION 
Total cholesterol, LDL, HDL and Triglyceride were estimated 
by enzymatic method. LDL cholesterol is calculated by using a 
standard WHO approved formula based on total cholesterol, HDL 
cholesterol and triglyceride values. 
LDL cholesterol= Total cholesterol – HDL cholesterol –  
triglyceride
5
 
VLDL cholesterol is calculated by using a standard WHO 
approved formula based on triglyceride values. 
VLDL = 
triglyceride
5
 
LIPOPROTEIN(A) ESTIMATION 
Lipoprotein(a) was estimated by spectrophotometry by 
measurement of the reflection or transmission properties of a material 
as a function of wavelength.  
Blood Hemoglobin, Sugar, Urea and Serum Creatinine were 
estimated using auto analyzer. 
 RESULTS 
 
Lipid parameters and lipoprotein(a) segment in cases were 
correlated with those of values for controls. 
 
Statistical Methods 
The significance of proportions of elevated lipoprotein (a) 
between cases and controls were found using  Fisher exact test and 
Chi-square test  Significance of lipid parameters, lab parameters and 
lipoprotein (a) between cases and controls were found using student t 
test.The strength of relationship is found using odds ratio. The effect 
size is calculated to find the relation of ishaemic stroke on lipoprotein 
(a). The Pearson Correlation Co-efficient is used to find the exact 
association between lipid profile and lipoprotein (a). 
CHI-SQUARE TEST 
Using chi-square test, the distribution of one or more sets of 
data, is tested whether there is a substantial difference between 
observed frequencies and expected frequencies. 
The chi-square distribution calculation formula is: 
 
Aij   =   actual frequency in the i'th row & j'th column 
 Eij   =   expected frequency in the i'th row & j'th column 
r   =   number of rows 
c   =   number of columns 
The chi-square test can then be used to conclude whether the 
value of this function is likely to have occurred by chance only, in 
independent sets of data. 
 
FISHER EXACT TEST 
Fisher's exact test is used to determine if there are nonrandom 
relations between two categorical variables. It is used to calculate the 
exact P value. 
Table 6:  Fisher Exact Test 
 Category 1 Category 2 Total 
Sample 1 a b a+b 
Sample 2 c d c+d 
Total a +c a +d n 
 
 
 STUDENT T- TEST (INDEPENDENT) 
Student T-Test is used to evaluate the differences in means 
between two groups. 
where   
PEARSON CORRELATION CO-EFFICIENT AND ITS 
SIGNIFICANCE TEST 
Pearson Correlation is a used to investigate the relationship 
between two quantitative, continuous variables. Pearson's correlation 
coefficient (r) is a quantity of the strength of the association between 
the two variables. 
 
Significance 
The t-test is used to prove if the correlation coefficient is 
significantly different from zero, and, hence that there is proof of a 
relationship between the two variables. There is then the fundamental 
assumption that the data is from a normal distribution sampled 
randomly. If this is not true, the verdicts may well be nullified. 
 
 
 Statistical Software and Tools  
Charts, Graphs and Tables were generated using Microsoft 
Excel and Microsoft Word. 
For writing Formulas and equations, Microsoft Math Input 
panel application was utilized. 
The data was analysed using statistical software packages, 
namely SPSS 17.0 and STATA Calc. 
 
STUDY DESIGN 
A case control study consisting 40 ischaemic cerebrovascular 
disease patients (Cases) and 40 normal individuals (controls) was 
undertaken to investigate the effect of lipoprotein (a), lipid profile, 
factors like diabetes, hypertension and smoking on stroke and 
association of lipoprotein (a) with lipid parameters. 
 AGE DISTRIBUTION 
The distribution of the cases and controls falling into different 
age groups are shown: 
Table 7:  Age Distribution 
Cases Controls 
Age in years 
No. % No. % 
≤ 30 1 2.5 4 10.0 
31-40 3 7.5 10 25.0 
41-50 12 30.0 8 20.0 
51-60 17 42.5 13 32.5 
61-70 7 17.5 5 12.5 
≥ 70 0 0.0 0 0 
Total 40 100.0 40 100.0 
Mean ± SD 52.25  ±  9.39 48.30  ±  12.06 
Inference Samples are age matched with p = 0.106 
SD- standard deviation 
 
 
 Fig 12: Age Distribution 
 
 
The mean age in our series was 52.25 years with SD 9.39 in the 
ischaemic stroke (cases) and 48.30 years with SD 12.06 in the 
controls. Since p>0.05 samples are matched for age. 
 
GENDER DISTRIBUTION 
The magnitudes of the cases and controls falling into different 
gender groups are estimated in this section. 
Table 8:  Gender Distribution 
Cases Controls 
Gender 
No. % No. % 
Male 25 62.5 23 57.5 
Female 15 37.5 17 42.5 
Total 40 100.0 40 100.0 
p = 1.000 
Inference : Samples are matched for gender ( p> 0.05) 
  
Fig 13: Gender Distribution of study population 
 
 
 
In our case series, 25 (62.5%) were males and 15 (37.5%) were 
females. Among the controls 23 (57.5%) were males and 17 (42.5%) 
were females. The samples are matched for gender. 
 
 
 RISK FACTORS DM, HYPERTENSION & SMOKING 
The prevalence of risk factors (Diabetes Mellitus, Hypertension 
and Smoking) among the Cases and Controls. 
Table 9:  Risk factors - DM, HTN & Smoking 
Cases Controls Risk 
Factors No. % No. % 
p Value 
DM 19 47.5 12 30.0 0.108 
Hypertension 17 42.5 11 27.5 0.160 
Smoking 21 52.5 16 40.0 0.262 
Inference 
The risk factors were increased in cases when 
compared to controls. 
 
The prevalence of risk factors (Diabetes Mellitus, Hypertension 
and Smoking) was higher in the cases in comparison to the controls, 
but was not statistically significant. 
 
Fig 14: Prevalence of Risk Factors in Study Population 
 LAB PARAMETERS 
The Lab Parameters (Hemoglobin, Urea and Serum Creatinine) 
are measured and evaluated for the affected individuals (Cases) 
against the normal individuals (Controls). 
Table 10:  Lab parameters 
Cases Controls Lab Parameters 
(Mean ± SD) 
Mean ± SD Mean ± SD 
p Value 
Hemoglobin 11.56 ± 2.57 11.18 ± 2.06 0.467 
Urea 39.40 ± 13.62 38.74 ± 15.92 0.844 
Serum Creatinine 1.16 ± 0.38 1.03 ± 0.32 0.105 
 
There was no significant difference in the levels of 
Hemoglobin, Urea and Serum Creatinine between cases and controls. 
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Fig 17: Distribution of Serum Creatinine 
LIPID PARAMETERS 
The Lipid Parameters (Total Cholesterol, LDL Cholesterol, 
HDL Cholesterol, and Triglycerides) are measured and evaluated for 
the affected individuals (Cases) against the normal 
individuals(Controls). 
Table 11:  Lipid parameters in cases and controls 
Cases Controls Lipid 
Parameters                
(Mean ± SD) Mean  SD Mean  SD 
p Value 
Total Cholesterol 178.00 ± 17.27 179.68 ± 30.75 0.765 
LDL Cholesterol 109.33 ± 21.84 108.73 ± 32.17 0.923 
HDL Cholesterol 37.30 ± 6.72 39.23 ± 4.12 0.127 
Triglycerides 156.93 ± 51.28 158.63 ± 52.71 0.884 
 
Total cholesterol, LDL Cholesterol, HDL Cholesterol, and 
Triglycerides between cases and controls are not significant as the p 
Value > 0.05 in all Lipid parameters. Total Cholesterol, HDL 
 Cholesterol, and Triglycerides are slightly reduced in  cases but, LDL 
Cholesterol  are   slightly  elevated  in cases compared  to  controls  
but  it  was not statistically significant  (p>0.05). 
 
Fig 18: Total cholesterol in study population 
 
 
Fig 19: Total LDL in study population 
 
  
Fig 20: HDL in study population 
 
 
Fig 21: Total triglyceride in study population 
 
 LIPOPROTEIN (A) IN CASES AND CONTROLS 
The significance of lipoprotein among the cases and controls is 
studied using the pooled standard deviation and the Effect Size in this 
section. 
Table 12:  Lipoprotein (a) in cases and controls 
Lipoprotein (a) Cases Controls 
Range 8.90 to 66.00 5.60 to 48.90 
Mean | Median 33.46 | 34.00 25.49 | 24.40 
Standard Deviation (SD) 15.05 10.17 
Sample Size ( n) 40 40 
Pooled Standard Deviation 12.842 
Uncorrected Effect Size (g) 0.6208 
Corrected Effect Size ( d ) 0.6148 
Lipoprotein (a) is significantly 
increased in cases 
Inference 
when compared to controls 
with p = 
0.007 
 
Lipoprotein (a) in Cases and Controls
33.46 25.49
0
5
10
15
20
25
30
35
40
Cases                                                             Controls
 
Fig 22: Lipoprotein (a) in study population 
 While comparing ischaemic stroke patients and controls for 
lipoprotein (a), the serum lipoprotein (a) levels in ischaemic stroke 
patients was found 33.46 ± 15.05 mg/dL (mean ± SD), which were 
significantly (p= 0.007) higher than  controls (25.49 ± 10.17 mg/ dL).   
 
ASSOCIATION OF LIPOPROTEIN (A) WITH STROKE 
The association of lipoprotein with the stroke is studied in this 
section for normal ( 0-30 ) and elevated levels ( >30 ) with Cases and 
Controls. 
 
Table 13:  Association of Lipoprotein (a) with Stroke 
Cases Controls Lipoprotein (a) 
In mg/dL No % No % 
Elevated ( > 30) 23 57.50 13 32.50 
Normal (0 - 30) 17 42.50 27 67.50 
Total 40 100 40 100 
Inference 
Patients with Lipoprotein (a) levels >30mg/dL are 2.81 
times more likely to have a Stroke with p = 0.025 
 
  
Fig 23: Association of Lipoprotein (a) with stroke 
Patients with Lipoprotein (a) levels >30mg/dL are 2.81 times 
more likely to have a Stroke than normal individuals. 
 
Pearson Correlation of Lipoprotein (a) with Lipid and Parameters  
The Pearson Correlation of Lipoprotein with total cholesterol, 
LDL Cholesterol, HDL Cholesterol and Triglycerides are measured 
and evaluated for the affected individuals (Cases) against the normal 
individuals (Controls). 
Classification of Correlation Co-efficient (r) 
Up to 0.1  Trivial correlation 
0.1-0.3  Small correlation 
0.3-0.5  Moderate correlation 
0.5-0.7  Large correlation 
0.7-0.9  Very large correlation 
  
Table 14:  Pearson Correlation of Lipoprotein (a) with Lipid 
Parameters 
Pearson Correlation of Lipoprotein (a) with Lipid Parameters 
Lipid Parameters Cases Controls 
Total Cholesterol -0.078 0.060 
LDL Cholesterol 0.006 -0.108 
HDL Cholesterol -0.095 -0.044 
Triglycerides -0.080 0.521 
 
The study proves that there inconsequential significance or only 
a small significance in few lipid parameters. Triglyceride levels are 
largely correlated in controls. 
 
Fig 24: Correlation of Lp (a)  Fig 25: Correlation of Lp (a) 
with cholesterol in cases   with cholesterol in controls 
 
 
 
  
Fig 26: Correlation of Lp (a)  Fig 27: Correlation of Lp (a) 
with LDL in cases   with LDL in controls 
 
  
Fig 28: Correlation of Lp (a)  Fig 29: Correlation of Lp (a)  
with HDL in Cases    with HDL in Controls 
 
  
Fig 30: Correlation of Lp (a)  Fig 31: Correlation of Lp (a)  
with triglycerides in Cases   with triglycerides in Controls 
 Mean Pattern of Lipoprotein (a) between different age groups 
This study is performed between the cases and controls to 
determine the significance of age group with lipoprotein. 
Table 15:  Mean Pattern of Lipoprotein (a) between different age 
groups 
Cases Controls 
Lipoprotein (a) 
Age in 
Years 
Mean ± SD Mean ± SD 
p Value 
≤ 60 32.71 ± 15.84 25.21 ± 10.69 0.0247 
> 60 37.00 ± 10.78 27.40 ± 5.60 0.101 
 
Patients aged 60 years or less with  ischemic brain infarct  had 
significantly elevated lipoprotein (a) with p= 0.0247 when compared 
with controls. Patients older than 60 years had elevated lipoprotein (a), 
levels but statistically insignificant (p=0.101). 
 
Fig 32: Distribution of Lipoprotein (a) in different age groups
 Association of Risk factors with Lipoprotein (a) 
This study is performed to analyze the association of risk 
factors with Lipoprotein(a). 
Table 16:  Association of Risk factors with Lipoprotein (a) 
Ischaemic Stroke 
Lipoprotein (a) mg/dl 
0 to 30 mg/dl > 30 mg/dl 
Risk Factors 
No.of Cases = 17 No.of Cases = 23 
p Value 
Smoking 7   (19.16) 14   (45.60) 0.469 
Hypertension 5   (16.48) 12   (43.90) 0.123 
Diabetes Mellitus 11   (20.14) 8   (48.05) 0.487 
 
 It is found that risk factors are not statistically significantly 
associated with Lipoprotein(a). 
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Fig 33: Association of Risk Factors with lipoprotein 
 Mean Pattern of Lipoprotein (a) in Normal TC and TG 
This study is performed to find the significance of Total 
Cholesterol and Triglycerides in Ischaemic stroke patients with normal 
controls. 
Table 17:  Mean Pattern of Lipoprotein (a) in Normal TC and TG 
Lipoprotein (a) 
Cases Controls Lipid Parameters 
Mean  ±  SD Mean  ±  SD 
p 
Value 
Total Cholesterol  
( ≤ 200 mg/dl ) 
25.55  ±  19.05 17.65  ±  12.29 0.030 
Total Cholesterol 
( > 200 mg/dl ) 
40.78  ±  14.14 29.05  ±  14.92 0.190 
Triglycerides 
( ≤ 160mg/dl) 
25.94  ±  21.22 13.98  ±  12.34 0.007 
Triglycerides  
( > 160mg/dl) 
29.12  ±  11.13 31.78  ±  7.08 0.422 
 
In our study, ischaemic stroke patients with total cholesterol          
(≤ 200 mg/dl) and triglycerides (≤ 160mg/dl) were found to have 
significantly elevated lipoprotein (a) with p Values of 0.030 and 0.007 
compared to matched controls.  
 
 
Fig 34: Mean pattern of lipoprotein in patients compared with TC 
and TG 
 DISCUSSION 
 
The study group comprised of 40 cases of ischemic stroke 
patients (25 male and 15 female subjects) and 40 controls (23 male 
and 17 female subjects) with an average age of 52.25 ± 9.39 years in 
ischemic stroke group and 48.30 ± 12.06 years in control groups. Both 
groups were matched for age and gender. 
There was no significant difference in laboratory parameters 
like hemoglobin, blood urea levels and serum creatinine levels 
between the two groups. 
While comparing lipid profile of cases and controls, there was 
no significant difference between cases and controls. Total cholesterol, 
HDL cholesterol and Triglycerides were slightly reduced in cases, but 
LDL cholesterol was slightly elevated in cases and these values were 
not statistically significant. The mean lipoprotein (a) levels in the case 
group was 33.46±15.05 mg/dL. The mean level in the control group 
was 25.49±10.17. The levels were significantly higher than the control 
group (p=0.007). 
Meta-analysis of data from about 31 studies, consisting of 
56010 patients with > 4609 stroke patients, in order to define the 
 possible association of Lp(a) and stroke revealed that Lp(a) is a risk 
factor for cerebrovascular disease.(99)  
Our study also correlated well with Jurgans G, Koltringer P(84) 
The Framingham heart study showed that elevated plasma Lipoprotein 
(a) was an independent predictor of stroke.(100)  
In our study, patients aged less than or equal to 60 years had 
significantly raised Lipoprotein(a) levels (p=0.0247). Patients aged 
more than 60 years had elevated Lp(a) levels though this was not 
statistically significant (p=0.101). 
Nagayama et al had reported higher lipoprotein levels in 
patients aged less than 45 years.(84)  
In a study conducted by the department of Medicine at Lady 
Hardinge medical college, New Delhi, it was found that serum 
lipoprotein levels in stroke cases were elevated (p< 0.001, OR 8.2). A 
positive correlation was observed between homocysteine and Lp(a) 
levels (r=0.75, p<0.001).(101)  
Lipoprotein(a) levels have been found to be genetically 
determined and influenced by apoliprotein gene on 6q 26-27. There is 
a  locus on chromosome 12p.13 and was associated with the increased 
risk of stroke.(102)  In our study, stroke patients are about three times 
more likely to have  raised lipoprotein (a) >30/dl. HDL Cholesterol 
 levels were slightly increased in control group but these were not 
statistically significant in comparison to the study group. The total 
cholesterol, LDL cholesterol, HDL cholesterol,   triglyceride levels 
was reduced in the case group in comparison to the control group, but 
the difference was not statistically significant. We found no or trivial 
correlation between lipid parameters and the study group. However a 
correlation was observed between Lp (a) and triglyceride levels in the 
control group (r=0.521). 
Similar to our study, studies conducted by Handan Misirli and 
colleagues.(103) found no significant correlation between various lipid 
parameters .HDL levels were not found to correlate with the risk of 
ischemic stroke in our study. This pattern of correlation was also 
observed by Gordon et al.(99)  
Our study reinforced the findings of earlier studies that found 
no significant correlation between LDL Serum cholesterol and the risk 
of stroke.(104)  
In our study, patients with total cholesterol levels (<200 mg  %) 
and normal total triglyceride levels (<160 mg%) had high Lp(a) levels 
which was found to be of statistical significance (p=0.030, p=0.007 
respectively) compared to that of controls. 
 Diabetes mellitus was found in 19 subjects (47.5%) of the cases 
and 12 subjects (30%) among controls. Hypertension was found in 17 
subjects (42.5 %) of the cases and 11 subjects (27.5 %) among 
controls. Smoking was found in 21 individuals (52.5%) among cases 
and 16 persons (40.0%) of the control groups. The risk factors were 
increased in cases when compared to controls but this increase is not 
statistically significant( p>0.05 for all risk factors). Our study 
population is from those admitted in our ward may be the 
representative of general population, so it is very unlikely to have 
selection bias. 
Thus, the results of this study prove that lipoprotein (a) has 
intense effect on ischemic stroke patients. 
 
 SUMMARY 
 
The study group consisted of total 80 subjects, 40 in the case 
group and 40 in the control group. Average age in cases group was 
52.25±9.39 years and in control group was 48.30±12.06 years. They 
were matched for age and gender. 
Serum lipid profile and lipoprotein (a) of 40 ischaemic stroke 
patients was studied and compared with those of the age and gender 
matched controls. 
The mean value of lipoprotein (a) was  significantly higher in 
the study group (33.46±15.05 mg/dL) when compared to the controls 
(25.49±10.17 mg/dL) with p=0.007 and also patients aged <60years 
had significantly elevated Lp(a) levels p=0.0247. 
The proportion of elevated lipoprotein (a) > 30 mg/dL was also 
significantly increased in cases when compared to the control group. 
Ischaemic stroke patients were 2.81 times more likely to have elevated 
lipoprotein (a) >30mg/dl with p=0.025. 
Ischaemic cerebrovascular disease patients with normal 
cholesterol levels (<200mg/dl) and normal triglyceride levels 
 (<160mg/dl) were found to have significantly raised Lp(a) compared 
to controls.  
The effect of hypertension, diabetes mellitus and smoking on 
lipoprotein (a) was studied and found to have no statistical 
significance. Serum lipids did not show statistical significance in study 
group when compared to the controls.  
 CONCLUSION 
 
 Ischemic stroke patients had higher levels of Lipoprotein (a). These 
were significant in comparison to the age and gender matched 
controls.  
 An elevated lipoprotein (a) level is an independent risk factor for 
ischaemic stroke, in individuals less than or equal to 60 years. 
 Ischemic Cerebro Vascular Disease patients with cholesterol levels 
<200 mg/dL and triglycerides level <160 mg/dL had significantly 
elevated lipoprotein (a) levels compared to controls. 
 This case-control study showed that the association of plasma lipid 
concentration with ischemic stroke was not statistically significant. 
 Cerebrovascular disease being the third most common cause for 
mortality, modification of Lp(a) levels at an early stage can be 
aimed at to reduce the overall risk of stroke and to prevent its 
occurrence in the future. 
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 PROFORMA 
 
Name :    Age :    Sex : 
Address :    IP Number : 
 
Chief Complaints : 
Diabetes : Duration :  Hypertension : Duration : 
  Treatment :     Treatment : 
 
Past History : 
 
Family History : 
 
Personal History : 
 Smoking 
 Alcohol 
 Others 
 
Menstrual History : 
Treatment History : 
 General Examination : 
Pulse Rate :    Blood Pressure : 
Respiratory rate :    Temperature : 
 
System Examination : 
 CVS 
 RS 
 P/A 
 CNS 
o Higher Mental Function 
o Speech :  
o Cranial Nerves : 
o Motor System : 
 Bulk 
 Tone 
 Power 
 Reflex  DTR 
Plantar response 
o Cerebellam 
o Extra pyramidal system 
Investigations : 
  Complete Haemogram 
 Fasting Blood Sugar (FBS):    (mg/dl) 
 Post prandial Blood sugar (PPBS):   (mg/dl) 
 Blood Urea        (mg/dl) 
 Serum Creatinine      (mg/dl) 
 Total Cholesterol (TC)     (mg/dl) 
 Triglyceride (TG)       (mg/dl) 
 High-density lipoprotein (HDL)   (mg/dl) 
 Low-density lipoprotein (LDL)    (mg/dl) 
 Very low-density lipoprotein (VLDL)   (mg/dl) 
 Lipoprotein (a)      (mg/dl) 
 Electro Cardiogram (ECG) 
 Echocardiogram (ECHO) 
 CT Scan 
 
 
 MASTER CHART - CASES 
Sl. 
No 
Name Age Sex 
IP 
Number 
DM HTN Smoking Hb Urea S.Creatinine ECG ECHO 
CT 
Scan 
TC LDL HDL VLDL TG 
LP 
(a) 
1 Jeyamurugan 51 M 35796 N N Y 15.9 31 1.1 WNL WNL Infract 212 139 40 33 166 39 
2 Purushothaman 40 M 43946 Y N Y 14.2 22 0.6 WNL WNL Infract 185 121 39 25 124 24.3 
3 Dhanapal 30 M 17017 N Y Y 16.3 42 1.2 WNL WNL Infract 183 141 20 22 112 62.9 
4 Thankaraj 60 M 12209 Y N Y 11.5 65 1.2 WNL WNL Infract 161 87 45 29 146 46 
5 Rathinam 55 M 49287 N Y Y 11 40 1 WNL WNL Infract 198 142 24 32 160 38.3 
6 Palaniammal 65 F 15928 Y Y N 16 29 1.2 WNL WNL Infract 190 138 28 24 122 15.4 
7 Palani 48 M 48082 N N Y 10.2 27 0.8 WNL WNL Infract 194 68 44 82 412 34 
8 Adbul Basha 67 M 5195 N Y N 9.9 38 1 WNL WNL Infract 186 99 47 40 202 36 
9 Rajendran 55 M 49354 N Y Y 10.3 48 0.8 WNL WNL Infract 166 98 33 35 174 32 
10 Lakshmi 51 F 18068 Y Y N 8 32 0.6 WNL WNL Infract 172 105 35 32 158 13.8 
11 Pachamutthu 55 M 18105 Y Y Y 13.2 26 1.6 WNL WNL Infract 164 99 39 26 132 66 
12 Radha 48 F 32167 N Y Y 18 27 0.9 WNL WNL Infract 186 119 40 27 135 22.3 
13 Jothy 42 F 24481 Y N N 9.8 24 0.8 WNL WNL Infract 158 89 36 33 163 24.2 
14 Murugasen 45 M 47362 N N Y 12 26 0.9 WNL WNL Infract 226 182 20 24 122 60.9 
15 Subramani 65 M 43931 N Y Y 11.3 27 0.7 WNL WNL Infract 174 105 40 29 146 46 
16 Chellayi 49 F 29106 Y N N 11.3 28 1.9 WNL WNL Infract 190 123 39 28 138 23 
17 Nadasen 43 M 19320 N N Y 8 23 1.4 WNL WNL Infract 164 103 35 26 129 16.3 
18 Pappu 60 F 32473 Y Y N 11.1 32 1.5 WNL WNL Infract 152 87 37 28 141 60.2 
19 Alamelu 45 F 33448 N N N 15.2 49 1 WNL WNL Infract 186 118 33 35 175 44.3 
20 Kandhan 60 M 46209 Y N N 6.9 50 1.2 WNL WNL Infract 149 79 38 32 162 22.2 
21 Chenniayapan 45 M 44048 Y N Y 9.3 38 1.8 WNL WNL Infract 168 102 39 27 136 48 
22 Kaliyappan 57 M 16905 Y N Y 13 34 1.2 WNL WNL Infract 206 126 41 39 195 28.2 
23 Sampoornam 55 F 34271 Y N N 12 44 0.9 WNL WNL Infract 187 125 39 23 116 14.3 
 24 Ponnamal 62 F 34896 Y N N 16 34 1.2 WNL WNL Infract 168 103 34 31 157 38.6 
25 Ponnuswamy 55 M 43990 N N Y 11 65 0.8 WNL WNL Infract 179 109 37 33 163 13.5 
26 Gowri 60 F 49604 Y Y N 12.4 36 1.1 WNL WNL Infract 191 123 35 33 166 10.3 
27 Indrani 44 F 49776 N N N 12.3 36 1.1 WNL WNL Infract 164 96 39 29 146 16.8 
28 Kanakaraj 59 M 48238 N N Y 10.3 36 2.1 WNL WNL Infract 178 114 40 24 118 8.9 
29 Murugan 48 M 13244 N N Y 10 42 0.9 WNL WNL Infract 192 128 40 24 120 34 
30 Palaniammal 65 F 15928 Y Y N 12.7 47 1.7 WNL WNL Infract 158 90 39 29 146 38 
31 Lakshmi 52 F 18068 Y N N 12.3 44 0.6 WNL WNL Infract 168 101 41 26 130 42 
32 Lakshmanan 65 M 34377 N N Y 9 30 1.3 WNL WNL Infract 159 82 46 31 156 49 
33 Venkattamal 67 F 38204 N Y N 11.2 46 1.1 WNL WNL Infract 164 99 39 26 132 36 
34 Veeramal 55 F 41681 Y N N 10.1 48 1.4 WNL WNL Infract 189 121 42 26 129 25.2 
35 Ramanathan 33 M 18099 Y Y N 10.3 70 1.6 WNL WNL Infract 162 100 38 24 121 45.6 
36 Kasi 42 M 38079 Y Y Y 10 32 1.3 WNL WNL Infract 176 114 20 42 210 20.6 
37 Perumal 55 M 43710 N Y Y 10 70 0.9 WNL WNL Infract 203 128 46 29 147 35 
38 Gopal 55 M 11279 N N N 8.9 71 0.8 WNL WNL Infract 178 83 41 54 270 27 
39 Madhu 37 M 12892 N N Y 7.9 24 1 WNL WNL Infract 156 84 39 33 164 47.3 
40 Ramsingh 45 M 50541 N Y N 13.6 43 2 WNL WNL Infract 178 106 45 27 136 32.9 
 
  
MASTER CHART - CONTROLS 
Sl. 
No 
Name Age Sex 
IP 
Number 
DM HTN Smoking Hb Urea S.Creatinine ECG ECHO TC LDL HDL VLDL TG 
LP 
(a) 
1 Krishnan 48 M 36499 N Y Y 12.1 52 1.1 NSR NS 158 82 39 37 185 30 
2 Mani 27 M 36469 N N Y 10.6 36 0.7 NSR NS 196 129 42 25 127 12.3 
3 Gopal 37 M 36480 Y N N 11.6 34 0.9 NSR NS 149 86 38 25 124 15.9 
4 Subramani 56 M 36489 N N N 8 26 1.1 NSR NS 185 117 41 27 134 13.6 
5 Palaniswamy 44 M 36542 N Y Y 11 42 1.2 NSR NS 151 74 39 38 190 24.9 
6 Chinnathalan 58 M 45102 N N Y 8 29 0.7 NSR NS 160 85 35 40 199 33.5 
7 Krishnan 65 M 13230 Y N Y 9.6 29 0.9 NSR NS 138 82 34 22 110 22.1 
8 Rajan 55 M 13429 Y Y N 10.6 40 1.2 NSR NS 142 82 38 22 111 18.6 
9 Rajendran 47 M 14907 N N Y 13.6 33 1.2 NSR NS 202 142 38 22 110 48.9 
10 Senthilrajan 37 M 19150 N N N 15.2 39 0.8 NSR NS 142 62 36 44 220 28.6 
11 Mary 40 F 50645 N Y N 11.6 20 0.9 NSR NS 233 175 35 23 115 12.3 
12 Sagunthala 51 F 50667 Y Y N 10.3 36 1.1 NSR NS 136 78 35 23 117 22.3 
13 Yasodha 47 F 51633 N N N 8 18 0.8 NSR NS 210 144 44 22 110 5.6 
14 Lakshmi 50 F 52920 Y N N 13 38 1.3 NSR NS 179 109 37 33 163 30.2 
15 Kamatchi 40 F 52890 N N N 9.8 40 0.7 NSR NS 116 61 30 25 124 22.3 
16 Alamelu 55 F 29042 Y N N 8.2 32 0.9 NSR NS 160 97 39 24 120 12.3 
17 Kamala 40 F 30607 N N N 10.9 63 1 NSR NS 174 100 42 32 162 24.8 
18 Ramanbee 60 F 34417 N Y N 6.9 89 1.6 NSR NS 212 137 35 40 200 43 
19 Lalitha 65 F 36991 Y N N 10.9 48 0.7 NSR NS 164 73 39 52 260 29 
20 Velliyammal 50 F 36944 N N N 13.6 28 0.7 NSR NS 164 82 40 42 208 37.3 
21 Kunjammal 58 F 39329 N N N 14.2 29 1.1 NSR NS 152 83 37 32 162 24 
 22 Anthoniyamma 40 F 39420 N N N 12.3 36 1.1 NSR NS 152 63 38 51 254 30.1 
23 Unnamalai 60 F 45120 Y N N 8 31 0.6 NSR NS 210 126 39 45 226 39.2 
24 Karupayee 68 F 47354 N Y N 11 32 0.9 NSR NS 148 86 38 24 121 23.8 
25 Gopal 57 M 38205 N N Y 13 28 1.1 NSR NS 218 113 37 68 340 40.1 
26 Subramani 56 M 38230 N Y Y 12.4 22 0.7 NSR NS 256 192 39 25 123 21.3 
27 Vellaiyan 60 M 38770 Y N N 14.6 29.8 0.8 NSR NS 174 101 41 32 162 31.4 
28 Ponnuswamy 60 M 40594 Y N Y 11 54 1.6 NSR NS 206 144 43 19 94 31 
29 Perumal 64 M 41743 N Y Y 11.6 62 1.3 NSR NS 196 111 44 41 206 25.8 
30 Balan 40 M 42902 N N Y 13 22 1 NSR NS 182 118 39 25 124 19.3 
31 Sithan 61 M 42976 N N N 9.8 26 0.9 NSR NS 166 88 50 28 140 36.3 
32 Periyaswamy 35 M 44043 N Y Y 7 64 1 NSR NS 190 125 41 24 121 12.9 
33 Chennakumar 25 M 45099 N N Y 12.6 23.8 0.8 NSR NS 169 84 43 42 208 23.9 
34 Soundarrajan 23 M 45123 N N Y 13 49 2.1 NSR NS 206 134 38 34 170 48.3 
35 Muthu 50 M 46149 Y N Y 10.4 28 0.9 NSR NS 215 135 46 34 170 28 
36 Kondappanayakkan 57 M 49378 Y N N 13.3 70 1.2 NSR NS 198 127 43 28 138 28.6 
37 Ganesan 37 M 49405 N N Y 12 44 0.6 NSR NS 213 163 29 21 104 15.6 
38 Chinnapillai 45 F 54203 N Y N 11.4 72 1.8 NSR NS 164 93 40 31 157 21.2 
39 Thenmozhi 25 F 44537 N N N 12.6 23 0.9 NSR NS 184 111 47 26 130 15.8 
40 Revathy 39 F 44486 N N N 10.4 32 1.1 NSR NS 217 155 41 21 106 15.3 
 
 LEGEND TO MASTER CHART 
 
CT Computed Tomography 
DM Diabetes Mellitus 
ECG Electrocardiogram 
ECHO Echocardiogram 
Hb Hemoglobin 
HDL High Density lipoprotein 
HTN Hypertension 
LDL Low Density Lipoprotein 
Lp (a) Lipoprotein a 
NS Normal Study 
TC Total Cholesterol 
TG Triglyceride 
VLDL Very Low Density Lipoprotein 
WNL Within Normal Limits 
Y Yes 
N No 
 
 
